Biogen (BIIB) 2025 Earnings Quality Report

Grade: C — Post-Humira Biogen Finds a New Floor

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Filed 2026-02-06, fiscal year ended December 31, 2025) + Yahoo Finance

Auditor: PricewaterhouseCoopers LLP — Clean opinion (1 Critical Audit Matter)

One-line verdict: Biogen's revenue stabilized in 2025 at $9.89B (+2.2%) after three years of decline from the $10.17B 2022 level. The growth came from the Reata Pharmaceuticals acquisition — SKYCLARYS (omaveloxolone) for Friedreich's ataxia generated $520.5M in 2025, QALSODY $86.9M, and ZURZUVAE $195.1M — while the legacy multiple sclerosis franchise (TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI) continues its slow decline. TYSABRI and SPINRAZA each still represent more than 10% of total revenue per the 10-K. LEQEMBI, Biogen's 50/50 Alzheimer's collaboration with Eisai, is ramping slowly. Cash flow is healthy — $2.20B CFFO against $1.29B net income, a 1.71x ratio — and free cash flow of $1.97B comfortably funds the zero dividend. The Altman Z-Score of 5.66 is the strongest in this batch. One red flag and two watch items: goodwill plus intangibles of $15.7B equals 86% of equity (D1 fail) largely because of the $6.9B Reata acquisition, cash of $3.0B covers 58% of $6.6B debt (C4 watch), and other soft assets grew 33.9% vs revenue growth of 2.2% (D3 watch). PwC's Critical Audit Matter flags Medicaid/managed care rebate reserves of $1.0B as the judgmental area.

Business: Post-Humira, Post-Aduhelm, Pivoting to Rare Disease

Per Item 1 of the 10-K: Biogen now organizes revenue into these product categories:

The 10-K explicitly discloses: "Product sales for TYSABRI and SPINRAZA each accounted for more than 10.0% of our total revenue for the years ended December 31, 2025, 2024 and 2023."

From the MD&A's discussion of specific products:

Total SPINRAZA revenue is approximately $1.55B. TYSABRI is a comparable magnitude. These two legacy products alone carry approximately 30% of total revenue.

The Reata acquisition ($6.93B in 2023) brought SKYCLARYS, the first FDA-approved treatment for Friedreich's ataxia. Annual revenue has ramped to $520M+ in its second full year — a reasonable trajectory but well short of the investment case that justified a $6.9B deal.

Profitability: R&D Rationalization in Progress

Per the consolidated statements of operations:

The MD&A explains the R&D decline: "The decrease in R&D expense was primarily driven by continued cost reduction measures realized in connection with our portfolio prioritization initiatives and our Fit for Growth program, offset in part by higher spend on clinical trials, including litifilimab."

The MD&A also notes: "Cost of sales increased $93.8 million, or 4.1% ... primarily due to a charge recorded during 2025 of approximately $104.9 million related to a litigation matter and product mix, including higher contract manufacturing revenue driven by the timing of batch releases."

Net income was impacted in 2025 by "Acquired IPR&D, upfront and milestone expense increased $410.3 million" and "Impairment of ROU asset of $52.9 million" — mix of one-time items.

Gross margin of 75.7% is in the normal biotech range. R&D intensity has dropped from 25% of revenue in 2023 to 18% in 2025, which the B3 check flags as passing but reflects a company in disciplined cost-cutting mode.

Cash Flow: Solid

Per the consolidated statements of cash flows:

CFFO of $2.20B exceeds net income of $1.29B by a 1.71x ratio, confirming C1 passes. Free cash flow of $1.97B gives Biogen substantial optionality — the company pays no dividend, so FCF is entirely available for debt paydown, share repurchases, and new acquisitions.

The 2023 acquisition outflow of -$6.93B was the Reata deal. 2024 included -$1.07B for HiBio/other deals. 2025 acquisition spending was zero — Biogen is in capital preservation mode.

The Balance Sheet: Post-Reata

The dramatic jump in Other Intangibles from $1,850M (2022) to $8,363M (2023) is entirely the Reata deal — primarily the SKYCLARYS IPR&D that became a definite-lived intangible upon FDA approval. The ratio is gradually improving from 99% to 86% as intangibles amortize.

D1 FAIL: Goodwill + intangibles of $15.7B = 86% of stockholders' equity. Flagged mechanically. The trajectory is improving.

C4 WATCH: Cash of $3.0B covers 46% of debt $6.6B. Biogen added $634M of cash in 2025 from free cash flow. There is no refinancing urgency — total debt has been stable or declining for two years.

D3 WATCH: Other assets grew 33.9% against revenue growth of 2.2%. The engine flags when soft asset growth significantly exceeds revenue growth — a potential revenue-smoothing warning. In Biogen's case, this is likely driven by deferred tax assets, operating lease ROU assets, or collaboration-related assets. It warrants a Note 11/12 footnote check.

The 18-Point Screening

Beneish M-Score components: DSRI 0.977 (below 1.0), GMI 1.006, AQI 0.958, SGI 1.022 (minimal growth), DEPI 0.841 (depreciation accelerated), SGAI 0.990, TATA -0.031, LVGI 0.911.

The DEPI of 0.841 is notably low — it suggests Biogen accelerated depreciation, likely tied to the SKYCLARYS acquired IPR&D intangible amortization schedule. This is the normal consequence of a large recent acquisition. Every other component is in normal range.

Altman Z-Score 5.66 — the strongest in this batch. Components: X1 working capital/assets 0.24, X2 retained earnings/assets 0.55, X3 EBIT/assets 0.08, X4 equity/liabilities 1.63. The high X2 reflects decades of prior profitability; the high X4 reflects a balanced capital structure.

Key Risks from the 10-K (Item 1A)

1. Legacy MS Franchise Decline

TYSABRI and TECFIDERA face ongoing biosimilar and generic competition. TECFIDERA lost U.S. exclusivity in 2020 and generic competition has eroded sales. Per the 10-K Item 1, these products still carry significant revenue but the trajectory is downward.

2. Single-Product Concentration in Rare Disease

TYSABRI and SPINRAZA each represent >10% of total revenue per the 10-K disclosure. Any safety signal, manufacturing disruption, or competitive product entry would materially affect results.

3. LEQEMBI Collaboration Execution

The 50/50 Alzheimer's collaboration with Eisai for LEQEMBI (lecanemab) is ramping slowly. The 2024 FDA approval is limited to early-stage Alzheimer's patients, requires PET imaging or CSF testing for amyloid confirmation, carries ARIA (amyloid-related imaging abnormalities) safety monitoring requirements, and faces Medicare reimbursement friction. The commercial trajectory has been weaker than bulls expected.

4. Reata / SKYCLARYS Payback

At $6.9B, the Reata acquisition priced SKYCLARYS at a significant revenue multiple. At $520M of 2025 revenue, the product is tracking below the bull case. Goodwill impairment risk on this asset is the largest single concentrated risk on the balance sheet.

5. Medicaid/Managed Care Rebate Estimation

Per PwC's Critical Audit Matter: "Within accrued expense and other, revenue-related reserves amounted to $1,000.4 million as of December 31, 2025. A portion of this balance includes contractual adjustments for Medicaid and managed care rebates in the U.S."

PwC explains why this is a CAM: "The principal considerations for our determination that performing procedures relating to reserves for Medicaid and managed care rebates in the U.S. is a critical audit matter are (i) the significant judgment by management due to the significant measurement uncertainty when developing the estimate of the reserves and (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating management's significant assumptions related to historical experience, current contractual requirements, specific known market events, and forecasted customer buying and payment patterns."

$1.0B of rebate reserves is the judgmental pool where a change in estimate could swing revenue and earnings.

Key Financial Trends (4-Year)

Summary

Grade: C. One red flag, two watch items, on a business that has stabilized after three years of revenue decline.

Biogen's 2025 10-K tells a coherent stabilization story. Revenue grew 2.2% to $9.89B — the first year of growth since 2022. SKYCLARYS, QALSODY, and ZURZUVAE together generated over $800M. The MS franchise continued to decline but at a manageable pace. R&D expenses fell 27% over two years from the "Fit for Growth" program. Free cash flow of $1.97B against $1.29B of net income gives management substantial optionality.

The screen returns:

The Beneish M-Score of -2.63 is below the manipulation threshold. The F-Score fraud probability of 0.65% is low. The Altman Z-Score of 5.66 is the strongest in this batch of 10 companies. PwC has audited Biogen since 2003 and issued a clean opinion with a single CAM on rebate reserves (standard for pharma).

The real questions about Biogen are operational, not accounting: Can SKYCLARYS justify the Reata purchase price? Will LEQEMBI growth accelerate with subcutaneous dosing? Can the rare-disease portfolio offset the MS franchise decline? The earnings quality screen says the reported numbers are trustworthy. The forward question is whether the trajectory is sustainable.

Read the 10-K. Read Note 19 on collaborative relationships (for LEQEMBI accounting). Read the revenue footnote (Note 5) on product sales by geography. Then decide.

**Disclaimer**: This report is based on Biogen's fiscal year 2025 10-K filed with the SEC on February 6, 2026. This is NOT investment advice.

**About EarningsGrade**: We screen earnings reports for financial red flags using an 18-point forensic framework. Grade C means a limited number of specific items warrant investigation.